Expiration date: 03/2025

International name: Terazosin

Group affiliation: Alpha1-blocker

Description of the active substance (INN): terazosin

Dosage Form: pills

Act:

Causes dilation of the arterioles and venules, reduces peripheral vascular resistance and venous return to the heart, has a hypotensive effect, promotes the normalization of lipid metabolism, helps to normalize urination

Composition:

terazosin 2 or 5 mg

Excipients: lactose monohydrate, microcrystalline cellulose, corn starch, talc, dye yellow (E104), colloidal anhydrous silica, magnesium stearate

Indications:

• Arterial hypertension
  
• prostate adenoma (symptomatic treatment)
  
• heart failure (in combination therapy).
  

Pharmachologic effect:

Blocker peripheral postsynaptic alpha1-adrenergic receptors. It causes dilation of the arterioles and venules, reduces peripheral vascular resistance and venous return to the heart, has a hypotensive effect. Onset of action - 15 min (single dose), the maximum effect is reached within 2-3 hours at a single dose to 6-8 weeks and - at repeated. The duration of the antihypertensive effect - 24 hours. With prolonged use is not accompanied by hypotensive effect usually reflex tachycardia. Promotes normalization of lipid metabolism: reduces total cholesterol, triglycerides, LDL and VLDL in the blood, increases the amount of HDL. The systematic use of marked regression of LV hypertrophy. Blocking alpha-1-adrenergic receptors of smooth muscles of the prostate and bladder neck, it helps to normalize urination in patients with benign prostatic hyperplasia.

Contraindications:

Hypersensitivity, hypotension, pregnancy, children's age. Angina pectoris, coronary heart disease or other. Urological diseases cardiovascular system, renal / hepatic failure, cerebrovascular disease, diabetes mellitus type 1.

Side effects:

Orthostatic hypotension (the phenomenon of "first dose" - often in combination therapy with diuretics or beta-blockers), collapse, palpitations, tachycardia, peripheral edema, fatigue, somnolence, disturbances of clarity of vision, nasal congestion, nausea, decreased potency, decreased hematocrit, of Hb, leukopenia, hypoproteinemia, hypoalbuminemia (due to hemodilution). Overdose. Symptoms: marked reduction of blood pressure, impaired coordination of movements, fainting. Treatment: put the patient by lowering the head end of the bed. If necessary - hypertensive drugs, in / in a liquid. Dialysis is ineffective.

Dosage and administration:

Inside, and hypertension at an initial dose - 1 mg / day with gradual increase until the desired effect. The maintenance dose - 1-10 mg 1 time per day, maximum daily dose - 20 mg. In benign prostatic hyperplasia initial dose - 1 mg / day before bed, with a gradual increase to 2-10 mg / day. The therapeutic effect is observed after 2 weeks after initiation of treatment. To achieve stable effect the course of treatment - 4-6 weeks.

Special instructions:

To avoid the phenomenon of the first dose of treatment should be started with a minimum effective dose (1 mg / day at bedtime), then the patient should be 6-8 hours in bed. The risk of orthostatic hypotension (the phenomenon of "first dose") in the highest 30 -90 min after drug administration and is elevated in patients concomitantly receiving beta-blockers and diuretics, with decreasing volume of fluid in the body, giposolevoy diet, and when resuming after interruption of treatment (several days). In case of temporary cessation of treatment therapy resumed with the same dose. In the treatment does not change the concentration of prostate specific antigen (PSA). Before initiation of therapy of benign prostatic hyperplasia is necessary to exclude prostate cancer. The effectiveness of the therapy in this disease was assessed after 4-6 weeks of treatment with maintenance doses. The patient should be informed about the increased risk of orthostatic hypotension with the use of ethanol, prolonged standing or performing physical exercise and in hot weather. Within 12 hours after the first dose, after an increase in dosage or discontinuation should be careful when driving and other lesson. Potentially hazardous activities that require high concentration and psychomotor speed reactions.

Interaction:

Beta-blockers, diuretics, BCCI, sympatholytic, ACE inhibitors increase the hypotensive effect. Adsorbents and antacids reduce the absorption. Adrenostimulyatorov weaken effect. NSAIDs (especially indomethacin) - may reduce the hypotensive effect due to suppression of the synthesis of Pg and / or fluid retention, and Na +.